Cheek Filler: Cost, Results and How Long It Lasts

Cheek filler is the everyday name for dermal fillers injected into the midface — the cheek area — to add volume and improve contour.

FDA describes dermal fillers as medical device implants approved to create a smoother and/or fuller appearance in the face, with cheeks among the areas its approvals name.

The labels' own wording varies by product: Juvéderm Voluma XC is approved for “cheek augmentation to correct age-related volume deficit in the midface” by deep (subcutaneous and/or supraperiosteal) injection, and Restylane Lyft for “cheek augmentation and correction of age-related midface contour deficiencies” by subcutaneous to supraperiosteal implantation — depth language that places the gel in the deeper layers of the midface, not within the skin itself.

The longest-approved cheek products are gels of crosslinked hyaluronic acid with lidocaine, a numbing agent: Allergan says several Juvéderm products use its proprietary VYCROSS technology, while Galderma's Restylane gels are bacterial-origin hyaluronic acid crosslinked with BDDE.

Revance and Teoxane market the RHA line — RHA 4 and RHA Dynamic Volume are its cheek-approved products — as hyaluronic acid fillers designed for dynamic movement.

Why cheeks hollow in the first place is mostly a story the manufacturers tell, so treat it as framing rather than settled science: Revance says its RHA Dynamic Volume filler addresses midface volume loss from factors such as aging, weight loss and sun damage, and Merz says rapid weight loss — especially from GLP-1 medications — can lead to visible facial hollowness or sagging.

One of the first quantitative looks at the GLP-1 question, a 2025 imaging study of 20 patients (mean weight loss 11.0 kg), measured a median 9.0% decrease in total midface volume, mostly from superficial fat pads.

For what treatment can and cannot do here, see whether filler can fix hollow cheeks.

Cheek volume filler is also not the only injectable aimed at the cheeks.

Allergan sells SkinVive by Juvéderm, an intradermal hyaluronic acid microdroplet injectable approved on 2023-05-11 to improve facial skin smoothness of the cheeks — Allergan markets it as a skin-quality treatment rather than a volumizer.

And Sculptra, a poly-L-lactic acid injectable its maker says works by stimulating the body's own collagen, holds an FDA cheek indication for fine lines and wrinkles in the cheek region, not for cheek volume.

Both are different purchases from cheek augmentation filler, and the sections below keep the three apart.

Start with who the labels actually cover.

Every US filler with a cheek indication is approved for adults: over 21 for Juvéderm Voluma XC, Restylane Lyft, Restylane Contour and saypha ChiQ, and 22 or older for RHA 4 and RHA Dynamic Volume.

The labels also record who was studied — and who was not.

Juvéderm's Important Safety Information states that Voluma XC safety was not studied in patients under 35 or over 65 for cheek augmentation.

“Not studied” is not the same as “proven unsafe”: it means the label carries no safety data for those groups, which is precisely the question to raise in a consultation rather than a ban.

The manufacturers frame their customer as someone with midface volume loss — Revance points to aging, weight loss and sun damage, and Merz to hollowing after rapid weight loss — but a label indication and a personal fit are different things.

A licensed injector's job is to examine your midface, ask what you want to change, and tell you plainly whether filler matches it.

What filler can and cannot do for your midface is judged in person, not from a product page — including this one.

The right outcome of a first visit is a specific plan naming the product, the volume and the price, or an honest “this is not the right tool for you.” For what results can look like, see cheek filler before and after.

“Best” is the wrong frame for fillers — no trial our research found crowns one — but “approved” has a precise answer.

As of 2026-10-20, six US filler products carry an FDA-approved cheek/midface indication.

Everything below that list — using a fold-only filler in the cheeks, or a poly-L-lactic acid injectable such as Sculptra for cheek volume — is an off-label use: it is not on any current US label for that product.

The cheek-approved products, from FDA's premarket approval records:

One date worth double-checking anywhere you see it: Voluma XC's temple approval carries the date 2023-10-06 — FDA's approval order for the temple indication is from 2023, and sources that date it to 2024 are wrong.

What about the head-to-head question — which of these is best?

The one head-to-head cheek trial our research found randomized Restylane Contour against Juvéderm Voluma XC, and the responder rates stayed close and swapped places over the year.

The study was sponsored by Galderma, Contour's maker, and was designed to test non-inferiority, not superiority — so it cannot fairly be read as ranking either product, and neither can anything quoting it.

Three look-alikes need care.

Sculptra is a poly-L-lactic acid injectable — its maker says it works by stimulating the body's own collagen — not a hyaluronic acid gel: its FDA cheek indication covers fine lines and wrinkles in the cheek region, not cheek volume or augmentation, so using it for cheek volume is off-label, and it is given as a series of sessions rather than one visit (Sculptra has its own guide).

Radiesse — an injectable implant whose main component is synthetic calcium hydroxylapatite — is approved for facial wrinkles and folds such as nasolabial folds, facial fat loss in people with HIV, the back of the hands, jawline contour (Radiesse (+)), and décolleté wrinkles diluted 1:2 with saline, but not for cheek augmentation.

And SkinVive by Juvéderm is approved for cheek skin smoothness, not cheek volume.

If a practice proposes any of the three “for cheeks,” ask directly which FDA indication covers the plan.

Filler is measured in milliliters (mL) and comes in syringes, so the two questions — how much filler, how much money — answer each other.

First, what the labels say.

The Restylane Lyft label caps cheek/midface treatment at 6.0 mL per treatment, and the Restylane Contour label caps each session at 6 mL in the cheeks and midface.

Read those as safety ceilings, not targets: a label maximum is the most a trial-tested protocol allows, not an amount to expect.

The trial numbers sit well below the ceilings.

In Restylane Contour's cheek trial, the median total volume for cheek augmentation was 3.80 mL for the initial and touch-up treatment combined — both sides together — and the median re-treatment volume at week 48 was 1.95 mL.

Those are medians from one product's study, not a dose; we found no label, professional-body standard or peer-reviewed source that gives a standard number of syringes per face area, so a per-person answer comes from the consultation, not from a chart like this.

On money: Allergan does not publish a Juvéderm price — it says only that pricing varies by the product, the amount used and the provider — and we could not confirm a published per-syringe price for any specific cheek filler from any manufacturer.

The broadest national figure is the American Society of Plastic Surgeons' cost page, which lists an average of $715 for hyaluronic acid fillers and $901 for non-HA fillers such as Radiesse and Sculptra.

Those are ASPS member-surgeon averages from its statistics — not med spa prices and not per-syringe prices for any named product.

For a fuller breakdown, see how much cheek filler costs.

What that leaves is the local quote, and the useful version is itemized: product name, milliliters per syringe, number of syringes planned, the fee, and what a touch-up costs if one is needed.

Two practices can quote very different totals for the same face because the product, the amount used and the provider differ — which is exactly why the breakdown matters more than the headline number.

The honest answer starts with the wording makers themselves use.

Allergan's stated duration for Voluma XC in the cheeks is “up to 2 years with optimal treatment” — an upper bound, tied by Allergan's own phrasing to optimal treatment, which often includes a touch-up.

It is not a promise and not a typical result, and Revance and Teoxane use the same “up to” structure for their RHA line, marketing results of “up to a year” in the cheeks.

The trial data is the soberer picture.

In the head-to-head cheek study — Restylane Contour against Juvéderm Voluma XC — blinded evaluators rated 91.2% of Contour subjects and 87.7% of Voluma subjects responders at week 12, 88.5% and 83.1% at week 24, 72.1% and 83.6% at week 36, and 62.8% and 65.1% at week 48, close to the one-year mark.

Responder rates decline rather than switch off, the lead changed hands as the year went on, and the study was sponsored by Galderma as a non-inferiority trial — so it shows two similar products fading on a similar curve, not a durability winner.

The re-treatment numbers say the same thing from another angle: the median volume at week-48 re-treatment in the Contour trial was 1.95 mL, against a 3.80 mL median for the initial plus touch-up treatment — a top-up, not a restart.

For the Restylane products we did not find a stated duration figure in their labels the way Allergan states one for Voluma; the responder rates are the concrete numbers to plan around.

Your own hold time depends on the product, the volume placed and your body — and our research found no trial that hands out a per-person number for cheek filler.

Start with the serious one.

FDA calls unintentional injection into a blood vessel the most concerning risk associated with dermal fillers: the chance is low, but a blocked vessel can cause tissue death (necrosis), vision abnormalities including blindness, or stroke.

Juvéderm's Important Safety Information carries the same warning in its own words — such complications “can be serious and may be permanent,” including vision abnormalities, blindness, stroke, temporary scabs or permanent scarring — and states that most of these events are irreversible.

The same ISI notes that the effectiveness of removing any dermal filler has not been studied.

Restylane's labels add a scoping detail worth reading no matter which product goes into your cheeks: rare ischemic events affecting the eye (vision loss) and the brain (stroke) have been reported after facial filler treatments, and in many of the events requiring medical intervention the injection was in the glabella, nose or periorbital area — sites outside the devices' approved indications.

The cheek is not one of the named sites; the warning describes facial filler treatments as a group.

The everyday end of the spectrum is milder.

Allergan reports that in the Voluma XC cheek study the most common side effects were tenderness, swelling, firmness, lumps/bumps, bruising, pain, redness, discoloration and itching — rated moderate, and generally lasting 2 to 4 weeks.

These are trial reports for one product, not a guarantee for any individual.

And on undoing it: Cleveland Clinic says hyaluronidase dissolves only hyaluronic acid fillers — wherever they sit, including the cheeks — and not other filler materials.

Dissolving filler is an off-label use of hyaluronidase: the drug's labels list three approved uses (an adjuvant for subcutaneous fluid administration, increasing dispersion and absorption of other injected drugs, and subcutaneous urography), and filler removal is not among them. “Reversible” is therefore not a promise to book a treatment around.

Who may place filler is a legal question before it is a shopping one.

AmSpa, the medical aesthetics trade association, describes injection of botulinum toxin as the practice of medicine — an FDA legend (prescription) drug being used to affect living tissue — to be performed by a physician, an independent-practice nurse practitioner or another licensed professional acting within their scope, under rules that vary by state.

Who may inject filler, and under whose supervision, is set by state law, so check the rules where you live rather than assuming a friend's state applies to yours.

Credentials vocabulary is its own subject: “RN,” “PA,” “NP” and “physician” are different licenses, and the rules around them vary by state — our credentials guide untangles them.

What matters at the consultation is narrower — the questions below, asked before anything is opened.

• Who will place the filler, and what license do they hold?
• Which product is planned, and which FDA indication covers this use?
• How many milliliters are budgeted, and how many syringes does that mean at your practice?
• What is the total price, and what does a touch-up cost if one is needed?
• How does the practice handle complications, and who answers the phone afterwards?

A consultation should feel like an examination, not a sales pitch.

If no one volunteers the product name, the volume, the price or the risks without prompting, treat that as information too — and if you feel rushed to commit on the day, you are allowed to book the treatment for a later date instead.